Ambeed 大中华区 CN | ZH

中文 - ZH English - EN

Ambeed.cn

搜索

关键字搜索批量搜索

首页 收藏 购物车0
首页 / 抑制剂/激动剂 /
其他抑制剂/激动剂
代谢酶
/ 脱羧酶 / Carbidopa

卡比多巴 /Carbidopa {[allProObj[0].p_purity_real_show]}

货号：A587591 同义名： (S)-(-)-Carbidopa

Carbidopa is an aromatic-L-amino-acid decarboxylase inhibitor with an IC50 of 29 ± 2 μM.

Carbidopa 化学结构 CAS号：28860-95-9
Carbidopa 化学结构
CAS号：28860-95-9
Carbidopa 3D分子结构
CAS号：28860-95-9
Carbidopa 化学结构 CAS号：28860-95-9
Carbidopa 3D分子结构 CAS号：28860-95-9
规格 价格 会员价 库存 数量
{[ item.pr_size ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]} 		{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_am, item.pr_size) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} 现货 咨询 - +
购物车0 收藏 询单

Carbidopa 纯度/质量文件 产品仅供科研

货号：A587591 标准纯度： {[allProObj[0].p_purity_real_show]}
批次查询： 批次纯度:

全球学术期刊中引用的产品

• Nat. Biomed. Eng., 2024, 8, 1412-1424. Ambeed. [ A538667 , A631746 ]
• JMC, 2024. Ambeed. [ A833302 , A475501 , A341986 , A356070 ]
• BMC Cancer, 2024, 24(1): 1415. Ambeed. [ A809692 , A209020 ]
• J. Am. Soc. Mass Spectrom., 2024, 35(12): 3192-3202. Ambeed. [ A166127 , A902473 , A753371 , A961334 , A292945 , A230770 , A300620 , A1114580 , A1159765 , A206238 ]
• PloS One, 2024, 19(11): e0308060. Ambeed. [ A302917 ]
更多 >
产品名称 decarboxylase ↓ 其他靶点 纯度
Eflornithine hydrochloride hydrate ✔ 98%
Methyldopa ✔ 98%
Benserazide HCI ✔ 98%
Carbidopa +++

aromatic-L-amino-acid decarboxylase, IC50: 29 μM

 		98%
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

Carbidopa 生物活性

靶点

  • decarboxylase

    aromatic-L-amino-acid decarboxylase, IC50:29 μM
描述 Aromatic L-amino acid decarboxylase (AADC) is the final enzyme in the biosynthesis of the monoamine neurotransmitters serotonin and dopamine, and dopamine is the precursor for norepinephrine and epinephrine[3]. Carbidopa (CD), a competitive inhibitor of AADC that doesn’t cross the blood-brain barrier, is routinely administered with levodopa (LD) to patients with Parkinson disease (PD) to reduce the peripheral decarboxylation of LD to dopamine[4]. On exposure to other human tumor lines, CD was lethal only to NCI-H146 and NCI-H209 small cell lung carcinoma (SCLC) lines (IC50 = 12 ± 1 μM and 22 ± 5 μM, respectively). CD (100 μM) decreased growth of SK-N-SH neuroblastoma and A204 rhabdomyosarcoma cells[5]. For all patients with cerebrospinal fluid (CSF), AUC (area under the curve) serum CD significantly correlated with percent-labeled CSF HVA (R = 0.786, p = 0.02). In addition, a significantly greater percent-labeled CSF HVA was present in “rapid” as compared to “slow” CD absorbers (Patients were divided into “slow” absorbers (those unable to attain a serum CD level of at least 300 ng/ml within 3 hours after CD administration) and those with more “rapid” absorption (patients obtaining a level of 300 ng/ml or greater within the first 3 hours))[4].

Carbidopa 临床研究

NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT01766258 Parkinson's Disease Phase 2 Completed - -
NCT01663935 Albinism Ocul... 展开 >>ocutaneous Albinism 收起 << Phase 2 Recruiting October 2017 United States, Wisconsin ... 展开 >> University of Wisconsin Recruiting Madison, Wisconsin, United States, 53705 Contact: Angie Wealti    608-265-7557    Angie Wealti    Principal Investigator: Michael C Struck, MD 收起 <<
NCT01468012 Cocaine Dependence Phase 2 Phase 3 Completed - United States, New York ... 展开 >> STARS New York, New York, United States, 10032 收起 <<

Carbidopa 参考文献

[1]Orlefors H, Sundin A, et al. Carbidopa pretreatment improves image interpretation and visualisation of carcinoid tumours with 11C-5-hydroxytryptophan positron emission tomography. Eur J Nucl Med Mol Imaging. 2006 Jan;33(1):60-5.

[2]Durso R, Evans JE, et al. Variable absorption of carbidopa affects both peripheral and central levodopa metabolism. J Clin Pharmacol. 2000 Aug;40(8):854-60.

[3]Wassenberg T, Molero-Luis M, Jeltsch K, et al. Consensus guideline for the diagnosis and treatment of aromatic l-amino acid decarboxylase (AADC) deficiency. Orphanet J Rare Dis. 2017;12(1):12

[4]Durso R, Evans JE, Josephs E, et al. Variable absorption of carbidopa affects both peripheral and central levodopa metabolism. J Clin Pharmacol. 2000;40(8):854‐860

[5]Gilbert JA, Frederick LM, Ames MM. The aromatic-L-amino acid decarboxylase inhibitor carbidopa is selectively cytotoxic to human pulmonary carcinoid and small cell lung carcinoma cells. Clin Cancer Res. 2000;6(11):4365‐4372

Carbidopa 实验方案

计算器
存储液制备 1mg 5mg 10mg

1 mM

5 mM

10 mM

4.42mL

0.88mL

0.44mL

22.10mL

4.42mL

2.21mL

44.20mL

8.84mL

4.42mL

Carbidopa 技术信息

CAS号28860-95-9
分子式C10H14N2O4
分子量 226.229
别名 (S)-(-)-Carbidopa
运输蓝冰
存储条件

液体 -20°C:3-6个月-80°C:12个月

粉末 Keep in dark place,Inert atmosphere,Store in freezer, under -20°C
溶解度

DMSO: 9 mg/mL(39.78 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO
动物实验配方

4% DMSO+30% PEG 300+2% Tween 80+water 1 mg/mL

Tags: Carbidopa | 28860-95-9 | (S)-(-)-Carbidopa | Aryl Hydrocarbon Receptor | Decarboxylase Inhibitor | Immunology/Inflammation | Aryl Hydrocarbon Receptor | 仅供科研使用 | AmBeed-信号通路专用抑制剂 | Carbidopa 纯度/质量文件 | Carbidopa 亚型比较 | Carbidopa 生物活性 | Carbidopa 临床数据 | Carbidopa 参考文献 | Carbidopa 实验方案 | Carbidopa 技术信息

Ambeed 相关网站 Ambeed.cn Ambeed.com
Ambeed
关于我们
联系我们
资讯中心
网站地图
产品手册
  • 批次文件查询
    • 客户支持
    技术支持
    专业术语
    缩略词释义
    质量手册
    产品咨询
    计算器
    活动政策
    订购方法
    积分商城
    活动声明
    联系我们
    400-920-2911 sales@ambeed.cn tech@ambeed.cn
    Ambeed 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质用途提供服务。

    尊敬的 Ambeed 客户您好，
    请您选择所在区域，我们将转接对应客服为您服务！

    热门区域

    A

    B

    C

    F

    G

    H

    J

    L

    N

    Q

    S

    T

    X

    Y

    Z

    热 A B C F G H J L N Q S T X Y Z